Brian D. Weiss, MD

Medical Director, Neuroblastoma Program

Associate Director of Clinical Research for Oncology

Associate Director for Safety and Compliance

Academic Affiliations

Professor, UC Department of Pediatrics

Phone 513-636-9863

Fax 513-636-3549

Email brian.weiss@cchmc.org

Targeted agents for neurofibromatosis type 1-related plexiform neurofibromas and other solid tumors; new therapies for high-risk neuroblastoma, including 131I-MIBG treatment and other new approaches to targeting and killing neuroblastoma cells.
Brian Weiss is a professor of Clinical Pediatrics in the Cancer and Blood Diseases Institute at Cincinnati Children’s Hospital Medical Center. There, he specializes in benign tumors in patients with Neurofibromatosis Type 1 (NF1), and directs the Neuroblastoma Program, in addition to serving as associate director of clinical research for Oncology, and associate director for Safety and Compliance. Dr. Weiss has spearheaded efforts to reduce chemotherapy errors and leads national trials in high risk neuroblastoma, targeted radiotherapy, and targeted drugs for NF1 associated plexiform neurofibromas.

MD: Northwestern University Medical School, Chicago, IL, 1993.

Residency and Chief Residency: Pediatrics, University of California, San Francisco, CA, 1993-1997.

Fellowship: Pediatric Hematology/Oncology, University of California, San Francisco, CA, 1997-2000.

Certification: National Medical Board; Pediatrics;1996, 2002; Pediatric Hematology-Oncology, 2000, 2007.

View PubMed Publications

Sharp SE, Trout AT, Weiss B, Gelfand M. MIBG in Neuroblastoma Diagnostic Imaging and Therapy. Radiographics. 2016 Jan-Feb;36(1):258-78.

Adams DM, Trenor CC 3rd, Hammill AM, Vinks AA, Patel MN, Chaudry G, Wentzel MS, Mobberley-Schuman PS, Campbell LM, Brookbank C, Gupta A, Chute C, Eile J, McKenna J, Merrow AC, Fei L, Hornung L, Seid M, Dasgupta AR, Dickie BH, Elluru RG, Lucky AW, Weiss B, Azizkhan RG. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics. 2016 Feb;137(2):1-10.

Dandoy CE, Hariharan S, Weiss B, Demmel K, Timm N, Chiarenzelli J, Dewald MK, Kennebeck S, Langworthy S, Pomales J, Rineair S, Sandfoss E, Volz-Noe P, Nagarajan R, Alessandrini E. Sustained reductions in time to antibiotic delivery in febrile immunocompromised children: results of a quality improvement collaborative. BMJ Qual Saf. 2016 Feb;25(2):100-9.

DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen EC, Giacomini KM, Weiss B, Cohn SL, Granger M, Yanik GA, Hawkins R, Courtier J, Jackson HA, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei DD, Villablanca JG, Marachelian A, Matthay KK. Phase 1 Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Clin Cancer Res. 2015 Jun 15;21(12):2715-21.

Yanik GA, Villablanca JG, Maris JM, Weiss B, Groshen S, Marachelian A, Park JR, Tsao-Wei D, Hawkins R, Shulkin BL, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas-Koga D, Hasenauer CB, Czarnecki S, Katzenstein HM, Matthay KK. I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study. Biol Blood Marrow Transplant. 2015 Apr;21(4):673-81.

Weiss B, Widemann BC, Wolters P, Dombi E, Vinks A, Cantor A, Perentesis J, Schorry E, Ullrich N, Gutmann DH, Tonsgard J, Viskochil D, Korf B, Packer RJ, Fisher MJ. Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol. 2015 Apr;17(4):596-603.

Salloum R, Garrison A, von Allmen D, Sheridan R, Towbin AJ, Adams D, Weiss B. Relapsed perinatal neuroblastoma after expectant observation. Pediatr Blood Cancer. 2015 Jan;62(1):160-2.

Emoto C, Fukuda T, Mizuno T, Cox S, Schniedewind B, Christians U, Widemann BC, Fisher MJ, Weiss B, Perentesis J, Vinks AA. Age dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1. Ther Drug Monit. 2015 Jun;37(3):395-9.

Plotkin SR, Albers AC, Babovic-Vuksanovic D, Blakeley JO, Breakefield XO, Dunn CM, Evans DG, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Kalamarides M, McClatchey AI, Messiaen L, Morrison H, Parkinson DB, Stemmer-Rachamimov AO, Van Raamsdonk CD, Riccardi VM, Rosser T, Schindeler A, Smith MJ, Stevenson DA, Ullrich NJ, van der Vaart T, Weiss B, Widemann BC, Zhu Y, Bakker AC, Lloyd AC. Update from the 2013 international neurofibromatosis conference. Am J Med Genet A. 2014 Dec;164A(12):2969-78.

Dandoy C, Davies S, Flesch L, Hayward M, Koons C, Coleman K, Jacobs J, McKenna L, Olomajeye A, Olson C, Powers J, Shoemaker K, Jodele S, Alessandrini E, Weiss B. A Team-Based Approach to Reducing Cardiac Monitor Alarms. Pediatrics. 2014 Dec;134(6)e1686-94.